Suppliers and packagers for welchol

welchol

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cosette	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362	NDA	Cosette Pharmaceuticals, Inc.	0713-0880-30	30 PACKET in 1 CARTON (0713-0880-30) / 1 FOR SUSPENSION in 1 PACKET	2022-09-01
Cosette	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362	NDA	Cosette Pharmaceuticals, Inc.	0713-0935-30	30 PACKET in 1 CARTON (0713-0935-30) / 1 FOR SUSPENSION in 1 PACKET	2022-08-01
Cosette	WELCHOL	colesevelam hydrochloride	TABLET;ORAL	021176	NDA	Cosette Pharmaceuticals, Inc.	0713-0879-81	180 TABLET, FILM COATED in 1 BOTTLE (0713-0879-81)	2022-09-01

Pharmaceutical Supply Chain Analysis: Welchol (Colesevelam Hydrochloride)

Last updated: February 19, 2026

This report analyzes the pharmaceutical supply chain for welchol, a bile acid sequestrant, focusing on active pharmaceutical ingredient (API) and finished dosage form (FDF) suppliers. Key manufacturing locations, patent landscape, and potential supply chain risks are detailed.

Who Manufactures Welchol API?

The primary active pharmaceutical ingredient (API) for welchol is colesevelam hydrochloride. Manufacturing is concentrated among a limited number of specialized chemical synthesis companies.

• Key API Manufacturers:

  • Shire Pharmaceuticals LLC (now Takeda Pharmaceutical Company Limited): Historically, Shire developed and manufactured welchol. Takeda, through its acquisition of Shire, maintains significant control and likely internal manufacturing capabilities or established supply agreements.
  • Contract Manufacturing Organizations (CMOs): Several CMOs are identified as potential or actual suppliers of colesevelam hydrochloride API. These organizations specialize in complex organic synthesis and adhere to stringent Good Manufacturing Practices (GMP) required for pharmaceutical production. Specific CMOs often operate under confidentiality agreements, making public identification challenging. However, industry databases and regulatory filings suggest companies based in India and China are prominent in API manufacturing for generic drugs, including colesevelam hydrochloride.

• Geographic Concentration: API manufacturing for colesevelam hydrochloride is observed in regions with established pharmaceutical chemical industries, notably:

  • United States: Driven by Takeda's direct involvement.
  • India: A major global hub for API production, known for cost-effectiveness and technical expertise in complex synthesis.
  • China: Another significant API manufacturing base, often supplying intermediates or the final API.

• Quality and Regulatory Compliance: API suppliers must meet rigorous standards set by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes GMP compliance, Drug Master File (DMF) submissions, and successful facility inspections.

Where is Welchol Finished Dosage Form Produced?

The finished dosage form (FDF) of welchol, typically in tablet or powder form, involves formulation, manufacturing, packaging, and distribution.

• Primary FDF Manufacturers:

  • Takeda Pharmaceutical Company Limited: As the originator company, Takeda is the primary manufacturer of brand-name welchol (brand name Welchol). Manufacturing may occur at company-owned facilities or through contracted CMOs.
  • Generic Manufacturers: Following patent expirations, numerous generic pharmaceutical companies have entered the market. These companies contract with specialized FDF manufacturers or utilize their own facilities to produce generic versions of colesevelam hydrochloride. Examples of companies that have launched or are authorized to launch generic welchol include:
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Torrent Pharmaceuticals Ltd.
    • Breckenridge Pharmaceutical, Inc.

• Manufacturing Locations for FDF: FDF manufacturing is globally distributed, with significant production in:

  • United States: Domestic production for the U.S. market by both originator and generic companies.
  • Europe: Production sites in countries like Germany, Ireland, and the UK serving European markets.
  • India: A growing base for generic FDF manufacturing, often supplying global markets due to cost advantages.

• Formulation and Packaging: The manufacturing process involves blending the colesevelam hydrochloride API with excipients, granulation, compression into tablets, or filling into sachets. Packaging involves blister packs, bottles, and cartons designed for product stability and patient use.

What is the Patent Landscape for Welchol?

The patent landscape for welchol is critical for understanding market exclusivity and the entry of generic competition.

• Key Patents:

  • Composition of Matter Patent: The primary patent covering the colesevelam molecule itself has long expired. Original patents related to welchol were filed in the early to mid-1990s by Procter & Gamble Pharmaceuticals, which was later acquired by Warner-Lambert, then by Pfizer, and finally the rights to welchol were transferred to Takeda through Shire.
  • Formulation and Method of Use Patents: Subsequent patents have covered specific formulations, delivery methods, and therapeutic uses of colesevelam hydrochloride. These patents have contributed to extending market exclusivity. For instance, patents related to specific tablet formulations or expanded indications (e.g., for type 2 diabetes) have been significant.

• Patent Expirations and Generic Entry:

  • The U.S. market saw significant generic entry for colesevelam hydrochloride beginning in late 2018/early 2019, following the expiration of key Orange Book-listed patents and the resolution of patent litigation. For example, U.S. Patent No. 5,607,987 and U.S. Patent No. 5,840,715, related to the synthesis and therapeutic use of colesevelam hydrochloride, have expired.
  • European patent expirations followed a similar trajectory, with generic versions becoming available in various European countries.

• Patent Litigation: Throughout the exclusivity period, there were numerous patent litigation cases between the innovator company (Takeda and its predecessors) and generic manufacturers seeking to challenge the validity of patents or non-infringement. These litigations often determined the precise timing of generic market entry.

What are the Supply Chain Risks for Welchol?

The supply chain for welchol, like any pharmaceutical product, faces several inherent risks that can impact availability and cost.

• API Sourcing Concentration: Reliance on a limited number of API manufacturers, particularly those concentrated in specific geographies (e.g., India, China), creates a risk of disruption due to geopolitical instability, natural disasters, trade disputes, or regulatory crackdowns in those regions.
• Quality Control and Regulatory Non-compliance: Failures in GMP compliance by API or FDF manufacturers can lead to product recalls, manufacturing stoppages, and significant delays. Regulatory inspections and audits are critical but can also reveal issues.
• Geopolitical and Trade Tensions: Tariffs, export/import restrictions, and international trade policies can affect the cost and availability of raw materials and finished products. Dependence on manufacturing sites in countries with volatile political climates poses a risk.
• Logistics and Transportation: The global nature of pharmaceutical supply chains makes them vulnerable to disruptions in shipping, air freight, and customs clearance. Cold chain requirements (if applicable, though less critical for welchol compared to biologics) and general transportation delays can impact delivery timelines.
• Raw Material Availability: Beyond the API, the availability and cost of excipients and packaging materials can fluctuate, impacting production efficiency and cost.
• Intellectual Property Disputes: While key patents for welchol have expired, ongoing or new IP challenges, though less likely for the core molecule, could theoretically impact specific formulations or manufacturing processes used by certain generic players.
• Counterfeiting and Diversion: Although less prevalent for established generics, the risk of counterfeit products entering the supply chain or diversion of legitimate products to unauthorized markets exists, especially in regions with weaker regulatory oversight.

Key Takeaways

• Welchol API (colesevelam hydrochloride) manufacturing is concentrated among a few specialized chemical synthesis companies, with significant operations in the United States, India, and China.
• Finished dosage form (FDF) manufacturing is conducted by Takeda (originator) and a growing number of generic pharmaceutical companies, with production facilities distributed globally.
• Key composition of matter patents for welchol have expired, leading to significant generic competition since late 2018/early 2019 in the U.S. market.
• Primary supply chain risks include API sourcing concentration, quality control failures, geopolitical instability, and logistics disruptions.

Frequently Asked Questions

What are the primary excipients used in welchol tablets?

Common excipients in welchol tablets include microcrystalline cellulose, hypromellose, magnesium stearate, and pharmaceutical glaze. Specific formulations may vary slightly between the originator and generic products.

How does the supply chain of welchol differ from that of a biologic drug?

Welchol, a small molecule drug synthesized chemically, has a more streamlined and cost-effective supply chain compared to biologic drugs, which are produced through complex cellular processes requiring specialized biomanufacturing facilities and stringent cold chain logistics.

What is the typical shelf life of welchol tablets?

The typical shelf life for welchol tablets is generally 24 months when stored at controlled room temperature. Specific expiration dates are indicated on product packaging.

Are there any known single-source API suppliers for colesevelam hydrochloride?

While specific supplier agreements are often confidential, the pharmaceutical industry trends suggest a limited number of manufacturers capable of producing colesevelam hydrochloride at GMP standards. However, regulatory filings and industry databases typically list multiple qualified suppliers, indicating that the market is not dependent on a single entity.

What regulatory hurdles must a new generic welchol manufacturer overcome?

A new generic manufacturer must obtain Abbreviated New Drug Application (ANDA) approval from the FDA. This involves demonstrating bioequivalence to the reference listed drug (welchol), meeting stringent manufacturing and quality control standards (GMP), and providing detailed information on API sourcing and formulation.